<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528086</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB00019885</org_study_id>
    <nct_id>NCT00528086</nct_id>
  </id_info>
  <brief_title>A Pilot, Randomized Controlled Trial of Group Visits for Persons With Parkinson's Disease</brief_title>
  <acronym>GROUP-PD</acronym>
  <official_title>A Single Center, Randomized Controlled, Pilot Study Comparing Group Visits Versus Routine Clinical Care for Participants With Parkinson's Disease (PD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Parkinson Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine patient satisfaction with group visits versus standard of care delivery for
      patients with Parkinson's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To establish the feasibility and to estimate the benefit of group visits for individuals with
      PD and their caregivers. The feasibility will be assessed by the ability to enroll and retain
      (measured by number of individuals who complete the 12-month study and at least half the
      study visits) ~40 individuals in the pilot trial. The responsiveness of the following
      different outcomes to group visits will be assessed during the pilot trial: quality of life,
      patient satisfaction, depression, caregiver burden, resource utilization, and disease
      progression. The primary outcome measure for efficacy will be a comparison of the change in
      the Parkinson's Disease Questionnaire-39 from baseline to 12 months in the control (routine
      care) and intervention (group visit) groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The feasibility (based on the ability to enroll and retain 40 individuals) and benefit (based on the 12-month change in PDQ-39) of group visits for individuals with Parkinson disease and their caregivers.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Parkinson's Disease Patient Caregivers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in group visit format.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in standard of care format (one-on-one physician-patient visits).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants will be recruited from Drs. Dorsey, Biglan, and Marshall's patient
        populations from the Parkinson disease clinic at the University of Rochester Neurology
        group.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of idiopathic Parkinson's disease as determined by having two of
             the four cardinal features of PD (rest tremor, bradykinesia, cogwheel rigidity, and
             gait instability) and no alternative explanation for the etiology of the symptoms

          -  Willing and able to provide informed consent and to participate actively in group
             visits and complete study activities

        Exclusion Criteria:

          -  Cognitive impairment, psychiatric disorder, or history of or current clinically
             significant substance abuse that in the investigator's judgment could interfere in the
             conduct of group visits or with study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Ray Dorsey, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Biglan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fred Marshall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Beck A, Scott J, Williams P, Robertson B, Jackson D, Gade G, Cowan P. A randomized trial of group outpatient visits for chronically ill older HMO members: the Cooperative Health Care Clinic. J Am Geriatr Soc. 1997 May;45(5):543-9.</citation>
    <PMID>9158573</PMID>
  </reference>
  <reference>
    <citation>Scott JC, Conner DA, Venohr I, Gade G, McKenzie M, Kramer AM, Bryant L, Beck A. Effectiveness of a group outpatient visit model for chronically ill older health maintenance organization members: a 2-year randomized trial of the cooperative health care clinic. J Am Geriatr Soc. 2004 Sep;52(9):1463-70.</citation>
    <PMID>15341547</PMID>
  </reference>
  <reference>
    <citation>Masley S, Phillips S, Copeland JR. Group office visits change dietary habits of patients with coronary artery disease-the dietary intervention and evaluation trial (D.I.E.T.). J Fam Pract. 2001 Mar;50(3):235-9.</citation>
    <PMID>11252212</PMID>
  </reference>
  <reference>
    <citation>Coleman EA, Grothaus LC, Sandhu N, Wagner EH. Chronic care clinics: a randomized controlled trial of a new model of primary care for frail older adults. J Am Geriatr Soc. 1999 Jul;47(7):775-83.</citation>
    <PMID>10404919</PMID>
  </reference>
  <reference>
    <citation>Trento M, Passera P, Tomalino M, Bajardi M, Pomero F, Allione A, Vaccari P, Molinatti GM, Porta M. Group visits improve metabolic control in type 2 diabetes: a 2-year follow-up. Diabetes Care. 2001 Jun;24(6):995-1000.</citation>
    <PMID>11375359</PMID>
  </reference>
  <reference>
    <citation>Wagner EH, Grothaus LC, Sandhu N, Galvin MS, McGregor M, Artz K, Coleman EA. Chronic care clinics for diabetes in primary care: a system-wide randomized trial. Diabetes Care. 2001 Apr;24(4):695-700.</citation>
    <PMID>11315833</PMID>
  </reference>
  <reference>
    <citation>Ickovics JR, Kershaw TS, Westdahl C, Rising SS, Klima C, Reynolds H, Magriples U. Group prenatal care and preterm birth weight: results from a matched cohort study at public clinics. Obstet Gynecol. 2003 Nov;102(5 Pt 1):1051-7.</citation>
    <PMID>14672486</PMID>
  </reference>
  <reference>
    <citation>Grosset KA, Grosset DG. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life. Mov Disord. 2005 May;20(5):616-9.</citation>
    <PMID>15719417</PMID>
  </reference>
  <reference>
    <citation>Shimbo T, Goto M, Morimoto T, Hira K, Takemura M, Matsui K, Yoshida A, Fukui T. Association between patient education and health-related quality of life in patients with Parkinson's disease. Qual Life Res. 2004 Feb;13(1):81-9.</citation>
    <PMID>15058790</PMID>
  </reference>
  <reference>
    <citation>Global Parkinson's Disease Survey (GPDS) Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord. 2002 Jan;17(1):60-7. doi: 10.1002/mds.10010.</citation>
    <PMID>11835440</PMID>
  </reference>
  <reference>
    <citation>Christakis NA, Allison PD. Mortality after the hospitalization of a spouse. N Engl J Med. 2006 Feb 16;354(7):719-30.</citation>
    <PMID>16481639</PMID>
  </reference>
  <reference>
    <citation>Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999 Oct;14(10):866-74.</citation>
    <PMID>10521886</PMID>
  </reference>
  <reference>
    <citation>Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord. 2006 Jan;12(1):35-41. Epub 2005 Nov 3.</citation>
    <PMID>16271496</PMID>
  </reference>
  <reference>
    <citation>Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):308-12.</citation>
    <PMID>10945804</PMID>
  </reference>
  <reference>
    <citation>Sławek J, Derejko M, Lass P. Factors affecting the quality of life of patients with idiopathic Parkinson's disease--a cross-sectional study in an outpatient clinic attendees. Parkinsonism Relat Disord. 2005 Nov;11(7):465-8. Epub 2005 Sep 9.</citation>
    <PMID>16154794</PMID>
  </reference>
  <reference>
    <citation>Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc. 1997 Jul;45(7):844-9.</citation>
    <PMID>9215336</PMID>
  </reference>
  <reference>
    <citation>Noyes K, Liu H, Li Y, Holloway R, Dick AW. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. Mov Disord. 2006 Mar;21(3):362-72.</citation>
    <PMID>16211621</PMID>
  </reference>
  <reference>
    <citation>Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res. 1995 Jun;4(3):241-8.</citation>
    <PMID>7613534</PMID>
  </reference>
  <reference>
    <citation>Marinus J, Ramaker C, van Hilten JJ, Stiggelbout AM. Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):241-8.</citation>
    <PMID>11796776</PMID>
  </reference>
  <reference>
    <citation>EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208.</citation>
    <PMID>10109801</PMID>
  </reference>
  <reference>
    <citation>Essink-Bot ML, Stouthard ME, Bonsel GJ. Generalizability of valuations on health states collected with the EuroQolc-questionnaire. Health Econ. 1993 Oct;2(3):237-46.</citation>
    <PMID>8275169</PMID>
  </reference>
  <reference>
    <citation>Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000 Jul;69(1):67-73.</citation>
    <PMID>10864606</PMID>
  </reference>
  <reference>
    <citation>Escobar GJ, Braveman PA, Ackerson L, Odouli R, Coleman-Phox K, Capra AM, Wong C, Lieu TA. A randomized comparison of home visits and hospital-based group follow-up visits after early postpartum discharge. Pediatrics. 2001 Sep;108(3):719-27.</citation>
    <PMID>11533342</PMID>
  </reference>
  <reference>
    <citation>Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983;17(1):37-49.</citation>
    <PMID>7183759</PMID>
  </reference>
  <reference>
    <citation>Ertan FS, Ertan T, Kiziltan G, Uyguçgil H. Reliability and validity of the Geriatric Depression Scale in depression in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1445-7.</citation>
    <PMID>16170093</PMID>
  </reference>
  <reference>
    <citation>Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc. 2004 May;52(5):784-8.</citation>
    <PMID>15086662</PMID>
  </reference>
  <reference>
    <citation>Zarit SH, Todd PA, Zarit JM. Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist. 1986 Jun;26(3):260-6.</citation>
    <PMID>3721233</PMID>
  </reference>
  <reference>
    <citation>Elmståhl S, Ingvad B, Annerstedt L. Family caregiving in dementia: prediction of caregiver burden 12 months after relocation to group-living care. Int Psychogeriatr. 1998 Jun;10(2):127-46.</citation>
    <PMID>9677500</PMID>
  </reference>
  <reference>
    <citation>Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993 Nov;43(11):2227-9.</citation>
    <PMID>8232934</PMID>
  </reference>
  <reference>
    <citation>Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2498-508.</citation>
    <PMID>15590952</PMID>
  </reference>
  <reference>
    <citation>Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427-42.</citation>
    <PMID>6067254</PMID>
  </reference>
  <reference>
    <citation>Montgomery GK, Reynolds NC Jr, Warren RM. Qualitative assessment of Parkinson's disease: study of reliability and data reduction with an abbreviated Columbia Scale. Clin Neuropharmacol. 1985;8(1):83-92.</citation>
    <PMID>3978653</PMID>
  </reference>
  <reference>
    <citation>Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9.</citation>
    <PMID>15817019</PMID>
  </reference>
  <reference>
    <citation>Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J; German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006 Aug 31;355(9):896-908. Erratum in: N Engl J Med. 2006 Sep 21;355(12):1289.</citation>
    <PMID>16943402</PMID>
  </reference>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2007</study_first_submitted>
  <study_first_submitted_qc>September 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2007</study_first_posted>
  <last_update_submitted>May 24, 2010</last_update_submitted>
  <last_update_submitted_qc>May 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>E. Ray Dorsey, MD, MBA</name_title>
    <organization>University of Rochester</organization>
  </responsible_party>
  <keyword>Group visits</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

